Scott GottliebMark B. McClellanTwo former FDA commissioners—Scott Gottlieb and Mark B. McClellan—warned that the Trump administration’s proposal to restructure FDA by consolidating the different product centers that review drugs, biologics, animal health, tobacco, and medical devices into a single regulatory office would lead to major challenges.
Amid continued anticipation about tariffs on pharmaceuticals, President Trump has signed an executive order to prioritize the onshoring of prescription drug manufacturing as part of his “America First” agenda.
FDA announced a meeting of the Oncologic Drugs Advisory Committee May 20 and 21. It will be the first ODAC meeting since President Trump was inaugurated.
President Trump nominated Casey Means as the U.S. surgeon general. Means, a wellness influencer, has “impeccable ‘MAHA’ credentials,” Trump wrote in a post on X.
The Association of American Cancer Institutes sent a letter to NIH Director Jay Bhattacharya expressing concern about the proposed NIH policy change that would centralize all grant reviews to the Center for Scientific Review (The Cancer Letter, March 7, 2025).
HHS spokesperson Andrew Nixon told NPR that HHS will reduce all contracts by 35%.
The National Cancer Registrars Association launched an advocacy campaign asking the public to contact their representatives and insist upon the protection of essential public health professionals and adequate funding of cancer prevention and research.
Over the past week, as cancer control experts scoured through a confidential budget document called the “passback” budget, they haven’t been able to find any trace of a relatively small but highly impactful program that funds state cancer registries.
On April 21, Women’s Health Initiative investigators were informed that HHS would be terminating the WHI Regional Center contracts at the end of the current fiscal year.
At least two medical journals have received letters from the Trump administration accusing them of political bias.
